CrystalGenomics Presents Phase 1 Clinical Trial of Blood Cancer Treatment CG-806 at American Society of Hematology Meeting

[Asia Economy Reporter Oh Ju-yeon] CrystalGenomics announced on the 6th that it will present the interim results of the Phase 1 clinical trial of the world's first blood cancer drug candidate 'CG-806' at the American Society of Hematology conference, held from the 5th to the 7th of next month (local time).

At this conference, two topics related to CG-806 will be presented.

First, the pharmacological inhibition of B-cell receptor-related kinases by CG-806 is expected to be presented, showing that it induces apoptosis and metabolic reprogramming in aggressive non-Hodgkin lymphoma (NHL) models.

Next, the dose-escalation Phase 1 a/b clinical trial of the non-dependent mutant BTK/FLT3 inhibitor CG-806 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or non-Hodgkin lymphoma (NHL) will also be covered.

CG-806 is the world's first disease-targeting FLT3/BTK multi-inhibitor drug candidate developed by CrystalGenomics.

In preclinical results conducted prior to Phase 1 clinical trials, CG-806 demonstrated more than 10 times stronger inhibitory activity against the disease-targeting FLT3 compared to Daiichi Sankyo and Aptuit's quizartinib, and showed powerful anticancer activity with cancer cell inhibitory effects ranging from 14 to 6,200 times stronger than AbbVie's BTK inhibitor ibrutinib against all malignant B-cell lymphoma cancer cells.

In August, Adam May, a researcher at Stone Lake Capital in the United States, released a report analyzing that "CG-806 has higher potential as a blood cancer treatment compared to active drugs such as AbbVie's ibrutinib, Merck's ARQ-531, and Lilly's LOXO-305" by comparing their preclinical profiles.

He explained, "In particular, CG-806 is differentiated from existing BTK inhibitors in that it inhibits not only BTK but also FLT3," adding, "It is expected to have a stronger effect than AbbVie's blockbuster ibrutinib, which generates over $7 billion annually."

CG-806 has received orphan drug designation from the U.S. Food and Drug Administration (FDA), allowing it to benefit from expedited review, conditional approval after Phase 2 clinical trials, and seven years of exclusive marketing rights.

This content was produced with the assistance of AI translation services.